Literature DB >> 9131465

Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection.

A H Brandenburg1, J Groen, H A van Steensel-Moll, E C Claas, P H Rothbarth, H J Neijens, A D Osterhaus.   

Abstract

The decline of maternal respiratory syncytial virus (RSV) specific serum antibodies was studied in 45 children during the first 6 months of life, using a virus neutralization assay and competition ELISAs measuring fusion protein and glycoprotein specific antibodies. In all children RSV neutralizing antibodies were demonstrated at birth, with titers ranging from 33 to 1382. The calculated mean half life of these antibodies was 26 days. Furthermore, in a group of 38 children with suspected RSV infection, all younger than 6 months of age on admission, the diagnostic value of serological assays was evaluated. In 32 children RSV infection was confirmed by virus isolation, direct immune fluorescence and RT-PCR. In 7 patients of this group a significant titer rise in virus neutralization assay was demonstrated. Six additional RSV infected children could be identified by showing the presence of RSV-specific IgM or IgA serum antibodies or by showing an increase in fusion protein or glycoprotein specific antibodies. All serological tests together identified 13 (41%) of the 32 RSV infected patients. It is concluded that in children of this age group, which represent the majority of patients hospitalized with RSV infections, serological assays not only have a limited diagnostic value but are of limited value for sero-epidemiological studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9131465     DOI: 10.1002/(sici)1096-9071(199705)52:1<97::aid-jmv16>3.0.co;2-y

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  50 in total

1.  Role of picornaviruses in flu-like illnesses of adults enrolled in an oseltamivir treatment study who had no evidence of influenza virus infection.

Authors:  Guy Boivin; Albert D Osterhaus; Annie Gaudreau; Helen C Jackson; Jan Groen; Penelope Ward
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

2.  Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh.

Authors:  Helen Y Chu; Mark C Steinhoff; Amalia Magaret; Khalequ Zaman; Eliza Roy; Gretchen Langdon; Mary Anne Formica; Edward E Walsh; Janet A Englund
Journal:  J Infect Dis       Date:  2014-06-05       Impact factor: 5.226

3.  Reversion of somatic mutations of the respiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship between association rate and neutralizing potency.

Authors:  John T Bates; Christopher J Keefer; Thomas J Utley; Bruno E Correia; William R Schief; James E Crowe
Journal:  J Immunol       Date:  2013-03-01       Impact factor: 5.422

4.  Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses.

Authors:  Richard Singleton; Nathalie Etchart; Sam Hou; Lisa Hyland
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

5.  Maternal transfer of RSV immunity in cotton rats vaccinated during pregnancy.

Authors:  Jorge C G Blanco; Lioubov M Pletneva; Raymonde O Oue; Mira C Patel; Marina S Boukhvalova
Journal:  Vaccine       Date:  2015-08-31       Impact factor: 3.641

Review 6.  Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.

Authors:  Matthew R Olson; Steven M Varga
Journal:  Expert Rev Vaccines       Date:  2008-10       Impact factor: 5.217

7.  Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.

Authors:  Bart G Jones; Robert E Sealy; Sherri L Surman; Allen Portner; Charles J Russell; Karen S Slobod; Philip R Dormitzer; John DeVincenzo; Julia L Hurwitz
Journal:  Vaccine       Date:  2014-04-14       Impact factor: 3.641

Review 8.  A multifaceted approach to RSV vaccination.

Authors:  Jorge C G Blanco; Marina S Boukhvalova; Trudy G Morrison; Stefanie N Vogel
Journal:  Hum Vaccin Immunother       Date:  2018-06-19       Impact factor: 3.452

9.  Identifying infections with respiratory syncytial virus by using specific immunoglobulin G (IgG) and IgA enzyme-linked immunosorbent assays with oral-fluid samples.

Authors:  Emelda A Okiro; Charles Sande; Martin Mutunga; Graham F Medley; Patricia A Cane; D James Nokes
Journal:  J Clin Microbiol       Date:  2008-02-27       Impact factor: 5.948

10.  The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya.

Authors:  Rachel Ochola; Charles Sande; Gregory Fegan; Paul D Scott; Graham F Medley; Patricia A Cane; D James Nokes
Journal:  PLoS One       Date:  2009-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.